title: MRSA infections: from classical treatment to suicide drugs.
abstract: Infections caused by the methicillin-resistant Staphylococcus aureus (MRSA) are today a major burden in nosocomial disease control. The global trend shows an alarming increase of MRSA infections as well as multi-drug resistance (MDR). The problem is exacerbated by the fact that infections with community-associated (CA) MRSA strains showing increased virulence and fitness add to infections with multi-drug resistant hospital-associated (HA) MRSA. The toxicity of pathogens and limited effectiveness of available treatment have led to high mortality rates and vast expenses caused by prolonged hospitalization and usage of additional antibiotics. Recently approved drugs still have classical targets and upcoming resistance can be expected. In a new approach by targeting co-factor syntheses of bacteria, the drug target and the affected pathways are uncoupled. This novel strategy is based on the thought of a classical pro-drug which has to be metabolized before becoming toxic for the bacterium as a dysfunctional co-factor, named suicide drug. Ideally these metabolizing pathways are solely present in the bacterium and absent in the human host, such as vitamin biosyntheses. This mini-review discusses current ways of MRSA infection treatment using new approaches including suicide drugs targeting co-factor biosyntheses.
authors.forename: Julia
authors.initials: J
authors.lastname: Drebes
authors.forename: Madeleine
authors.initials: M
authors.lastname: Künz
authors.forename: Claudio A
authors.initials: CA
authors.lastname: Pereira
authors.forename: Christian
authors.initials: C
authors.lastname: Betzel
authors.affiliation: Unit for Drug Discovery, Department of Parasitology, Institute of Biomedical Science, University of Sao Paulo, Sao Paulo, Brazil. cwrenger@icb.usp.br.
authors.forename: Carsten
authors.initials: C
authors.lastname: Wrenger
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D013203:Staphylococcal Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents